Study on clinical features of early death in older patients with acute promyelocytic leukemia
- PMID: 39725701
- DOI: 10.1007/s00277-024-06165-1
Study on clinical features of early death in older patients with acute promyelocytic leukemia
Abstract
This study aimed to analyze the baseline clinical characteristics, as well as the clinical features and risk factors of early death (ED) in older patients with acute promyelocytic leukemia (APL). A retrospective analysis was conducted on 198 consecutive older patients (age ≥ 50 years) with newly diagnosed APL who received arsenic trioxide alone as induction therapy, with 354 younger patients (age < 50 years) as controls. Ten easily obtainable clinical parameters were selected. Compared with the younger group, the older group had less fever, lower white blood cell (WBC) count, lower levels of albumin, and higher levels of creatinine upon admission. While the younger group had higher levels of aspartate aminotransferase and lower levels of fibrinogen (all P < 0.05). The ED rate was significantly higher in the older group (21.7% vs. 12.4%; P = 0.004). The causes of ED in the older group were bleeding, infection, embolism, differentiation syndrome, and others, in order of incidence. The cumulative incidence of ED due to infection (P = 0.0003) and embolism (P = 0.034) was significantly higher in the older group. For the older patients, independent risk factors for ED were WBC count > 5.9 × 109 /L, albumin < 35.85 g/L, creatinine > 72.9 µmol/L and fibrinogen < 1.137 g/L; independent risk factor for bleeding ED was WBC count > 6.2 × 109 /L; while independent risk factors for infection ED were albumin < 36.55 g/L and fibrinogen < 1.035 g/L. The baseline clinical characteristics, the clinical features and risk factors of ED in older APL patients were all quite different from those in younger patients, so research specifically targeting older patients with APL is very necessary.
Keywords: Acute promyelocytic leukaemia; Arsenic trioxide; Early death; Older.
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Conflict of interest statement
Declarations. Competing interests: The authors declare no competing interests.
Similar articles
-
Comparative analysis of causes and predictors of early death in elderly and young patients with acute promyelocytic leukemia treated with arsenic trioxide.J Cancer Res Clin Oncol. 2020 Feb;146(2):485-492. doi: 10.1007/s00432-019-03076-x. Epub 2019 Nov 4. J Cancer Res Clin Oncol. 2020. PMID: 31686248 Free PMC article.
-
Analysis of risk factors for early death in patients with acute promyelocytic leukaemia treated with arsenic trioxide.Ann Hematol. 2022 May;101(5):1039-1047. doi: 10.1007/s00277-022-04788-w. Epub 2022 Feb 16. Ann Hematol. 2022. PMID: 35174404
-
Factors affecting thrombohemorrhagic early death in patients with acute promyelocytic leukemia treated with arsenic trioxide alone.Blood Cells Mol Dis. 2019 Nov;79:102351. doi: 10.1016/j.bcmd.2019.102351. Epub 2019 Aug 1. Blood Cells Mol Dis. 2019. PMID: 31400712
-
Early predictor for differentiation syndrome in newly diagnosed acute promyelocytic leukaemia patients treated with single-agent arsenic trioxide.Ann Hematol. 2024 Oct;103(10):3947-3954. doi: 10.1007/s00277-024-05776-y. Epub 2024 Apr 29. Ann Hematol. 2024. PMID: 38684509 Review.
-
Risk factors and remaining challenges in the treatment of acute promyelocytic leukemia.Int J Hematol. 2024 Nov;120(5):548-555. doi: 10.1007/s12185-023-03696-7. Epub 2024 Feb 22. Int J Hematol. 2024. PMID: 38386203 Review.
References
-
- Lehmann S, Ravn A, Carlsson L et al (2011) Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish adult Acute Leukemia Registry. Leukemia 25(7):1128–1134. https://doi.org/10.1038/leu.2011.78 - DOI - PubMed
-
- Park JH, Qiao B, Panageas KS et al (2011) Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid. Blood 118(5):1248–1254. https://doi.org/10.1182/blood-2011-04-346437 - DOI - PubMed - PMC
-
- Micol JB, Raffoux E, Boissel N et al (2014) Management and treatment results in patients with acute promyelocytic leukaemia (APL) not enrolled in clinical trials. Eur J Cancer 50(6):1159–1168. https://doi.org/10.1016/j.ejca.2013.11.023 - DOI - PubMed
-
- Paulson K, Serebrin A, Lambert P et al (2014) Acute promyelocytic leukaemia is characterized by stable incidence and improved survival that is restricted to patients managed in leukaemia referral centres: a pan-canadian epidemiological study. Br J Haematol 166(5):660–666. https://doi.org/10.1111/bjh.12931 - DOI - PubMed
-
- Gill H, Raghupathy R, Lee CYY et al (2023) Acute promyelocytic leukaemia: population-based study of epidemiology and outcome with ATRA and oral-ATO from 1991 to 2021. BMC Cancer 23:141. https://doi.org/10.1186/s12885-023-10612-z - DOI - PubMed - PMC
MeSH terms
Substances
LinkOut - more resources
Full Text Sources